The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

Abstract Background and Purpose This update of the treatment guidelines was
commissioned by the European Academy of Neurology and the European section of the …

Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected
source for cell-based therapies for Parkinson's disease (PD). The regulatory criteria for the …

We report the implantation of patient-derived midbrain dopaminergic progenitor cells,
differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient …

Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to
treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively …

Parkinson's disease (PD) usually presents in older adults and typically has both motor and
non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from …

Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia
nigra leading to disabling deficits. Dopamine neuron grafts may provide a significant …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Astrocytes play important roles in numerous central nervous system disorders including
autoimmune inflammatory, hypoxic, and degenerative diseases such as Multiple Sclerosis …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …